Literature DB >> 25364995

Diversion of methadone and buprenorphine from opioid substitution treatment: a staff perspective.

Björn Johnson1, Torkel Richert.   

Abstract

Opioid substitution treatment (OST) is still controversial, despite positive results. The issue of diversion to the illicit drug market is a cornerstone in the criticism typically voiced against the treatment. Little research is available concerning how professionals who work in OST view the issue of diversion. In this article, we discuss existing ideas and attitudes toward diversion of methadone and buprenorphine among OST staff in Sweden. The article is based on semi-structured interviews with 25 professionals working in eight OST-programs in southern Sweden. Diversion was seen as a deleterious phenomenon by the interviewees. Three problematic aspects were highlighted: medical risks in the form of overdose fatalities and the recruitment of new opiate/opioid users; negative consequences for the legitimacy of OST; and moral objections, since diversion means that the patients remain in a criminal environment. However, positive aspects were also highlighted. Illicit methadone or buprenorphine is perceived as safer than heroin. In this way, diversion can fulfill a positive function; for instance, if there is a shortage of access to regular treatment. Patients who share their medication with opioid-dependent friends are seen as less culpable than those who sell to anyone for money.

Entities:  

Keywords:  buprenorphine; diversion; illicit use; methadone; opioid substitution treatment; staff perspective

Mesh:

Substances:

Year:  2014        PMID: 25364995     DOI: 10.1080/02791072.2014.960109

Source DB:  PubMed          Journal:  J Psychoactive Drugs        ISSN: 0279-1072


  5 in total

1.  A systematic review of patients' and providers' perspectives of medications for treatment of opioid use disorder.

Authors:  Katharine Cioe; Breanne E Biondi; Rebecca Easly; Amanda Simard; Xiao Zheng; Sandra A Springer
Journal:  J Subst Abuse Treat       Date:  2020-09-22

2.  Barriers to Medications for Opioid Use Disorder Among Veterans Involved in the Legal System: a Qualitative Study.

Authors:  Andrea K Finlay; Erica Morse; Matthew Stimmel; Emmeline Taylor; Christine Timko; Alex H S Harris; David Smelson; Mengfei Yu; Jessica Blue-Howells; Ingrid A Binswanger
Journal:  J Gen Intern Med       Date:  2020-06-24       Impact factor: 5.128

3.  Long-term self-treatment with methadone or buprenorphine as a response to barriers to opioid substitution treatment: the case of Sweden.

Authors:  Torkel Richert; Björn Johnson
Journal:  Harm Reduct J       Date:  2015-02-18

4.  Barriers and facilitators to buprenorphine use for opioid agonist treatment: protocol for a scoping review.

Authors:  Pamela Leece; Triti Khorasheh; Kimberly Corace; Carol Strike; Ahmed M Bayoumi; Sheena Taha; Elisabeth Marks; Beata Pach; Keith Ahamad; Erin Grennell; Melissa Holowaty; Heather Manson; Sharon E Straus
Journal:  BMJ Open       Date:  2019-12-15       Impact factor: 2.692

5.  Therapy without a prescription: buprenorphine/naloxone diversion and the therapeutic assemblage in Taiwan.

Authors:  Jia-Shin Chen
Journal:  Sociol Health Illn       Date:  2019-12-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.